Bank of America
KYTX icon

Bank of America’s Kyverna Therapeutics KYTX Stock Holding History

Bank of America’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-300
Closed -$7.45K – 8460
2024
Q1 		$7.45K Buy
+300
New +$8.37K ﹤0.01% 6938

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Bank of America's KYTX Position: Q1 2026 in Review

Bank of America increased its Kyverna Therapeutics (KYTX) stake by 94% in Q1 2026, buying an estimated $225K and bringing the position to 55,728 shares worth $481K. The position accounts for ﹤0.01% of the portfolio, ranked #4921.

Bank of America first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Bank of America held 55,728 shares of Kyverna Therapeutics worth $481K as of Q1 2026.
  • Bank of America bought 27,019 Kyverna Therapeutics shares in Q1 2026, an estimated $225K.
  • Kyverna Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4921 holding.
  • Bank of America first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.